|
Re: The importance of sub-group analyses
|
3
|
Resverlogix Corp.
|
Dec 18, 2018 08:42PM
|
|
The HDL hypothesis lives on
|
3
|
Resverlogix Corp.
|
Dec 18, 2018 07:50PM
|
|
Re: "top line data on or before January 31, 2019" A Covenant of the loan
|
3
|
Resverlogix Corp.
|
Dec 18, 2018 05:27PM
|
|
The importance of sub-group analyses
|
6
|
Resverlogix Corp.
|
Dec 18, 2018 05:18PM
|
|
Re: A New Frontier in CV Risk Reduction for Patients With Type 2 Diabetes
|
4
|
Resverlogix Corp.
|
Dec 18, 2018 02:26PM
|
|
Re: Lowest volume in a long time?
|
2
|
Resverlogix Corp.
|
Dec 18, 2018 10:16AM
|
|
Re: A New Frontier in CV Risk Reduction for Patients With Type 2 Diabetes
|
4
|
Resverlogix Corp.
|
Dec 17, 2018 03:11PM
|
|
Re: Biotech Showcase
|
3
|
Zenith Epigenetics
|
Dec 17, 2018 12:32PM
|
|
Re: 2019 Potential Events
|
2
|
Resverlogix Corp.
|
Dec 17, 2018 12:32PM
|
|
Re: Bioasis To Present at Investor & Industry Conferences in January 2019
|
2
|
BIOASIS TECHNOLOGIES INC
|
Dec 17, 2018 12:31PM
|
|
Biotech Showcase
|
2
|
Zenith Epigenetics
|
Dec 17, 2018 12:24PM
|
|
Re: 2019 Potential Events
|
1
|
Resverlogix Corp.
|
Dec 17, 2018 12:23PM
|
|
Re: A New Frontier in CV Risk Reduction for Patients With Type 2 Diabetes
|
3
|
Resverlogix Corp.
|
Dec 17, 2018 11:52AM
|
|
A New Frontier in CV Risk Reduction for Patients With Type 2 Diabetes
|
5
|
Resverlogix Corp.
|
Dec 17, 2018 10:02AM
|
|
Re: MD&A out
|
2
|
Resverlogix Corp.
|
Dec 15, 2018 04:35PM
|
|
Re: MD&A out
|
1
|
Resverlogix Corp.
|
Dec 15, 2018 10:25AM
|
|
Re: MD&A out
|
1
|
Resverlogix Corp.
|
Dec 14, 2018 10:58PM
|
|
Re: CANTOS good, but FDA not on board with sub-group analysis
|
4
|
Resverlogix Corp.
|
Dec 14, 2018 03:17PM
|
|
Re: MD&A out
|
3
|
Resverlogix Corp.
|
Dec 14, 2018 02:26PM
|
|
ERA-EDTA 2018 Symposium Presentations "Epigenetics in CKD & CVD: A potential breakthrough therapy?"
|
1
|
Resverlogix Corp.
|
Dec 14, 2018 01:32PM
|
